Plant Name: Aralia continentalis
Taxonomic Information:
Plant ID: NPO3127
Plant Latin Name: Aralia continentalis
Taxonomy Genus: Aralia
Taxonomy Family: Araliaceae
Plant External Links:
NCBI TaxonomyDB:
287721
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CDC25B; | |
| RECQL; AKR1B10; AKR1B1; | |
| CA12; CA9; | |
| RORC; | |
| NR1H4; | |
| APP; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2A13 | Cytochrome P450 2A13 | Q16696 | CHEMBL3542436 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 3.565E-09 | 3.882E-05 | AKR1B1, AKR1B10, APP, CYP1A2, CYP2A6, NR1H4 |
| MF | GO:0005488; binding | GO:0046914; transition metal ion binding | 3.530E-08 | 2.562E-04 | APP, CA12, CA9, CYP1A2, CYP2A13, CYP2A6, NR1H4, RORC |
| BP | GO:0008152; metabolic process | GO:0044281; small molecule metabolic process | 5.891E-08 | 3.207E-04 | AKR1B1, AKR1B10, APP, CA12, CA9, CYP1A2, CYP2A13, CYP2A6, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.421E-07 | 1.054E-03 | CYP1A2, CYP2A13, CYP2A6 |
| MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 3.538E-07 | 1.284E-03 | CYP2A13, CYP2A6 |
| MF | GO:0003824; catalytic activity | GO:0016712; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | 4.725E-07 | 1.470E-03 | CYP1A2, CYP2A13, CYP2A6 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 4.464E-18 | 6.384E-16 | CA12, CA1, CA2, CA5A, CA7, CA6, CA9, CA14 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.566E-10 | 1.120E-08 | HSD11B1, CYP2C9, CYP2A6, CYP2A13, CYP2D6, CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.603E-10 | 1.718E-08 | HSD11B1, CYP2C9, CYP2A6, CYP2A13, CYP1A2, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 6.423E-09 | 1.837E-07 | CYP2C9, CYP2A6, CYP2D6, CYP1A2, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.652E-09 | 1.306E-07 | CYP2C9, PLA2G1B, CYP1A2, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.403E-07 | 5.727E-06 | CYP2C9, CYP2A6, CYP1A2, ALDH1A1, CYP3A4 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 3.630E-06 | 7.416E-05 | CYP2C9, APP, CYP2D6, MAPK1, CYP2C19 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 3.551E-05 | 5.078E-04 | HSD11B1, CYP2C9, CYP2A6, AKR1B10, PLA2G1B, CYP1A2, ALDH1A1, AKR1B1, CYP2C19, CYP3A4, HSD17B10 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 1.737E-05 | 2.912E-04 | PTPN1, MAPK1, ACP1, PTPRF |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 1.832E-05 | 2.912E-04 | CASP7, CASP1, MAPK1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05134 | Legionellosis | 2.094E-04 | 2.495E-03 | CASP7, CASP1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 4.891E-04 | 3.885E-03 | XPO1, CASP1, MAPK1, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 2.988E-04 | 2.848E-03 | CYP2C9, PLA2G1B, CYP2C19 |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05010 | Alzheimer's disease | 4.192E-04 | 3.747E-03 | APP, CASP7, MAPK1, HSD17B10 |
| 09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 2.328E-04 | 2.504E-03 | CASP1, MAPK1, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.452E-04 | 2.504E-03 | HSD11B1, CYP1A2, CYP3A4 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 4.456E-04 | 3.749E-03 | CA2, NR1H4, CYP3A4 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05132 | Salmonella infection | 7.807E-04 | 5.876E-03 | CASP1, MAPK1, NFKB1 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 4.288E-05 | 5.574E-04 | CYP2A6, CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | APP; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; |
| C00-D49: Neoplasms | Cancer | C00-C96 | APP; CDC25B; CA9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP; |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP; |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| C00-D49: Neoplasms | Glioma | C71 | APP; |
| NA: NA | Geographic retinal atrophy | NA | APP; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | APP; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
